>Marché européen de la gestion des maladies musculo-squelettiques (MSK), par type (système de biofeedback numérique, applications numériques axées sur les maladies musculo-squelettiques, solutions et autres), technologie (technologie de mouvement de précision, technologie de vision par ordinateur et autres technologies), type d'intégration (téléphone, tablette, ordinateur et autres), modalité (thérapie virtuelle, thérapie en personne, thérapie personnalisée/personnalisée et autres), application (applications préopératoires et postopératoires), population de patients (pédiatrie, adultes et gériatrie), utilisateur final (hôpitaux et cliniques, maisons de retraite , centres de santé, centres de réadaptation, établissements de soins de santé virtuels/à domicile et autres) - Tendances et prévisions de l'industrie jusqu'en 2030.
Analyse et perspectives du marché européen de la gestion des maladies musculo-squelettiques (MSK)
La demande croissante d’avancées technologiques dans le diagnostic des maladies MSK, la sensibilisation croissante aux maladies MSK, la prévalence croissante de la polyarthrite rhumatoïde (PR) et l’augmentation des cas de fractures osseuses sont les facteurs qui devraient stimuler la croissance du marché.
D’autre part, les initiatives stratégiques des acteurs du marché, le développement de produits, l’utilisation de la télémédecine dans la gestion des maladies musculo-squelettiques et l’utilisation accrue des MDA et des soins à domicile pour la gestion des maladies musculo-squelettiques peuvent constituer une opportunité de croissance du marché.
Cependant, le coût élevé du diagnostic et du traitement des maladies orthopédiques et l’augmentation de l’utilisation de médicaments puissants dans le traitement des douleurs musculo-squelettiques devraient freiner la croissance du marché.
La demande croissante d'utilisation de la gestion des maladies musculo-squelettiques (MSK) dans le développement et la conception de médicaments devrait stimuler la croissance du marché en Europe. Data Bridge Market Research analyse que le marché européen de la gestion des maladies musculo-squelettiques (MSK) connaîtra un TCAC de 22,2 %, au cours de la période de prévision de 2023 à 2030.
|
Rapport métrique |
Détails |
|
Période de prévision |
2023 à 2030 |
|
Année de base |
2022 |
|
Année historique |
2021 (personnalisable de 2023 à 2030) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD, prix en USD |
|
Segments couverts |
Par type (système de biofeedback numérique, applications numériques axées sur l'appareil locomoteur, solutions et autres), technologie (technologie de mouvement de précision, technologie de vision par ordinateur et autres technologies), type d'intégration (téléphone, tablette, ordinateur et autres), modalité (thérapie virtuelle, thérapie en personne, thérapie personnalisée et autres), application (applications préopératoires et postopératoires), population de patients (pédiatrie, adultes et gériatrie), utilisateur final (hôpitaux et cliniques, maisons de retraite, centres de santé, centres de réadaptation, établissements de soins de santé virtuels/à domicile et autres) |
|
Pays couverts |
Allemagne, France, Royaume-Uni, Italie, Espagne, Russie, Turquie, Belgique, Pays-Bas, Danemark, Suisse, Suède, Pologne, Norvège, Finlande et reste de l'Europe |
|
Acteurs du marché couverts |
RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH and Limber Health, Inc. among others |
Market Definition
Musculoskeletal (MSK) disease or impairments comprise more than 150 different diseases or conditions, which internally affect the human system and are characterized by deficiencies in the muscles, bones, joints and adjacent connective tissues, which lead to lifelong hindrances in functioning and participation. The conditions are characterized by pain, limited gait movement and dexterity thereby, reducing people’s aptitude to work and participate in society.
The management of MSK diseases involves consultation with a physician, integrated with telemedicine, which is the use of Digital Biofeedback Systems (DBSs), MDAs and therapies. Physical activity and weight management programs are also important self-management activities for persons with arthritis. Virtual therapy or remote consultation entails a holistic approach with the implementation of video conference and phone consultations in MSK practice.
- In the coming future, important decisions related to MSK disease management on physical movement and post-surgery applications will be made by individuals who not only understand telemedicine and virtual technology but, can also use MSK disease management tools and the knowledge they release to develop hypotheses and identify quality targets.
Europe Musculoskeletal (MSK) Disease Management Market Dynamics
Drivers
- Technological advances in the diagnosis of musculoskeletal disorders (MSDS)
Musculoskeletal (MSK) diseases are injuries and disorders that affect the movement of the human body in the MSK system, such as muscles, ligaments, nerves, tendons, cartilage and discs. Some of the common MSK conditions are myasthenia gravis, Osteoarthritis (OA), gout, RA, back pain, osteoporosis and Systemic Lupus Erythematosus (SLE). MSK pain has various causes, for example, muscle tissue can be damaged by wear and tear during daily activities. The strain on human body parts due to sprains, car accidents, falls, jerky movements, fractures, dislocations and direct muscle blows also cause MSK pain.
- Increasing cases of bone fractures
A fracture is the medical definition of a broken bone. Fractures are usually the result of injuries such as falls, car accidents, or sports injuries. However, certain medical conditions and repetitive forces (such as running) can increase the risk of certain types of fractures. If more pressure is put on a bone than it can withstand, it will crack or break. A fracture of any size is called a fracture. If the fracture pierces the skin, it is called an open fracture (compound fracture). A stress fracture is a fracture resulting from repeated or prolonged forces against the bone. Repeated stress weakens the bone until it eventually breaks.
Opportunities
- Use of telemedicine in musculoskeletal (MSK) disease management
Telemedicine provides patients with cost-effective, quality care. Previsit planning allows appropriate implementation of telemedicine, which ensures that the patients and physicians be provided with functional telemedicine equipment. Physicians for the treatment of MSK diseases perform a structured MSK examination via telemedicine. The use of common household items enables physicians to replicate in-person clinical examination maneuvers. Home care instructions and online rehabilitation provide initial management of treatment.
- Strategic initiatives by key market players
The rise in Musculoskeletal (MSK) diseases increases the need for strategic business ideas. It includes partnership, business expansion, collaboration and other developments. In the Europe musculoskeletal (MSK) disease management market, many health agencies and market players entail initiatives that are designed to deliver returns on investments to the customers. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.
Restraints/Challenges
- High cost of diagnosis and treatment of orthopedic diseases
Chronic orthopedic diseases such as arthritis and bursitis affect the MSK system- most often the bones or joints. They can cause pain and dysfunction, making normal daily activities difficult. These conditions are different from orthopedic injuries, such as a dislocated shoulder or broken bone, which are often caused by sudden trauma. Unlike accidental or traumatic orthopedic injuries, chronic conditions are usually progressive, starting slowly and worsening or developing over time. They may be genetic or age-related, or they may be caused by overuse.
Some orthopedic conditions are treatable and some cannot be cured at this time but can be treated to reduce pain and improve quality of life. Accurate diagnosis and targeted treatment can help reduce problems even in progressive conditions without treatment. Treatment recommendations depend on the type and severity of your condition. Treatments range from RICE (Rest, Ice, Compression and Elevation) to major surgery.
- Rise in use of heavy-duty drugs in treating MSK pain
MSK pain is a challenging condition for patients and physicians. Many adults, regardless of age, gender, or economic status, have experienced one or more episodes of MSK pain at some point in their lives. It affects about 47% of the population. About 39% to 45% of them are long-term problems that require a doctor's consultation. Inadequately treated MSK pain can reduce the quality of life and cause serious socioeconomic problems.
Multimodal analgesia and multidisciplinary approaches are key elements in the effective treatment of MSK pain. Both pharmacological, non-pharmacological and interventional pain management are important to improve the patient's recovery, well-being and quality of life. Thus, recent guidelines recommend preventive strategies and physical tools to reduce drug use. In patients who have not responded adequately to treatment, the appropriate use of interventional pain management and other alternative techniques is critical to the safe and effective treatment of patients with chronic pain.
Post-COVID-19 Impact on Europe Musculoskeletal (MSK) Disease Management Market
During the pandemic, the symptoms of MSK disease management remain existed following recovery from COVID-19, with the most common complaints including fatigue, back pain, arthralgia, myalgia, low back pain and neck pain. The management of MSK disease increases the use of virtual therapy telemedicine and digital rehabilitation service.
In the COVID-19 pandemic environment, telehealth is feasible for healthcare providers to provide rehabilitation services for their patients with various MSK conditions. Current evidence suggests that for some MSK diseases, telehealth evaluation may be reliable, treatment may be effective and patient satisfaction may be good or better than for in-office care.
Recent Developments
- In April 2022, Airrosti Rehab Center, LLC formed a partnership with Buoy Health’s innovative healthcare marketplace. The partnership resulted to bring good value MSK care to Buoy’s more than 2 million users per month and the development of novel MSK virtual products.
- In March 2022, DarioHealth Corp. formed a contractual agreement with Sanofi U.S. The agreement focused on the acceleration of commercial growth for DarioHealth Corp. in MSK disease management digital portfolio and the development of Digital Health Solutions on the DarioHealth Corp. platform.
Europe Musculoskeletal (MSK) Disease Management Market Scope
Europe musculoskeletal (MSK) disease management market is segmented into seven notable segments based on type, technology, integration type, modality, application, patient population and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Digital Biofeedback System
- Musculoskeletal-focused Digital Apps (MDAS)
- Solutions
- Others
Based on type, the market is segmented into digital biofeedback system, musculoskeletal-focused digital apps (MDAs), solutions and others.
Technology
- Precision Motion Technology
- Computer Vision Technology
- Other Technologies
Based on technology, the market is segmented into precision motion technology, computer vision technology and other technologies.
Integration Type
- Phone
- Tablet
- Computer
- Others
En fonction du type d'intégration, le marché est segmenté en téléphone, tablette, ordinateur et autres
Modalité
- Thérapie virtuelle
- Thérapie en personne
- Thérapie personnalisée
- Autres
En fonction des modalités, le marché est segmenté en thérapie virtuelle, thérapie en personne, thérapie personnalisée/personnalisée et autres.
Application
- Applications préopératoires
- Applications post-opératoires
En fonction de l’application, le marché est segmenté en applications pré-opératoires et applications post-opératoires.
Population de patients
- Pédiatrie
- Adultes
- Gériatrie
En fonction de la population de patients, le marché est segmenté en pédiatrie, adultes et gériatrie.
Utilisateur final
- Hôpitaux et cliniques
- Maisons de retraite
- Centres de santé
- Centres de réadaptation
- Cadres de soins de santé virtuels/à domicile
- Autres
En fonction de l’utilisateur final, le marché est segmenté en hôpitaux et cliniques, maisons de retraite, centres de santé, centres de rééducation, établissements de soins de santé virtuels/à domicile et autres.
Analyse/perspectives régionales du marché de la gestion des maladies musculo-squelettiques (MSK) en Europe
Le marché européen de la gestion des maladies musculo-squelettiques (MSK) est analysé et des informations et tendances sur la taille du marché sont fournies par région, type, technologie, type d'intégration, modalité, application, population de patients et utilisateur final, comme référencé ci-dessus.
Les pays couverts par ce rapport de marché sont l'Allemagne, la France, le Royaume-Uni, l'Italie, l'Espagne, la Russie, la Turquie, la Belgique, les Pays-Bas, le Danemark, la Suisse, la Suède, la Pologne, la Norvège, la Finlande et le reste de l'Europe. L'Allemagne devrait dominer le marché en raison des initiatives croissantes des acteurs du marché et de l'utilisation accrue d'outils technologiques modernes.
La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques européennes et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact sur les canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché de la gestion des maladies musculo-squelettiques (MSK) en Europe
Le paysage concurrentiel du marché européen de la gestion des maladies musculo-squelettiques (MSK) fournit des détails sur le concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, la présence en Europe, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises par rapport au marché.
Certains des principaux acteurs opérant sur le marché européen de la gestion des maladies musculo-squelettiques (MSK) sont RecoveryOne, Kiio, Omada Health Inc., DarioHealth Corp., IncludeHealth, kaia health, IMC., Wellness Coaches USA, LLC, Sparta Science, Movement RX, Phzio, Airrosti Rehab Center, LLC, SimpleTherapy, Inc., Hinge Health, Inc., Sword Health, Inc., SPRITE HEALTH et Limber Health, Inc. entre autres.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE SEGMENT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 THE CATEGORY VS TIME GRID
2.13 SECONDARY SOURCES
2.14 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCE
4.3 KEY STRATEGIC INITIATIVES
4.4 EMERGING TREND ANALYSIS OF DIGITAL REHABILITATION AND DIGITAL PHYSIOTHERAPY IN THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET
4.4.1 DIGITAL REHABILITATION
4.4.2 DIGITAL PHYSIOTHERAPY
5 EPIDEMOLOGY
5.1 US
5.2 CANADA
5.3 MEXICO
5.4 GERMANY
5.5 FRANCE
5.6 U.K.
5.7 ITALY
5.8 SPAIN
5.9 RUSSIA
5.1 TURKEY
5.11 BELGIUM
5.12 DENMARK
5.13 NETHERLANDS
5.14 SWITZERLAND
5.15 SWEDEN
5.16 POLAND
5.17 NORWAY
5.18 FINLAND
5.19 CHINA
5.2 JAPAN
5.21 SOUTH KOREA
5.22 INDIA
5.23 AUSTRALIA
5.24 NEW ZEALAND
5.25 SINGAPORE
5.26 THAILAND
5.27 MALAYSIA
5.28 VIETNAM
5.29 TAIWAN
5.3 INDONESIA
5.31 PHILIPPINES
5.32 BRAZIL
5.33 ARGENTINA
5.34 SOUTH AFRICA
5.35 SAUDI ARABIA
5.36 BAHRAIN
5.37 U.A.E
5.38 KUWAIT
5.39 OMAN
5.4 QATAR
5.41 EGYPT
5.42 ISRAEL
6 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 TECHNOLOGICAL ADVANCES IN THE DIAGNOSIS OF MUSCULOSKELETAL DISORDERS (MSDS)
7.1.2 RISING AWARENESS ABOUT MUSCULOSKELETAL DISORDERS (MSDS)
7.1.3 GROWING PREVALENCE OF RHEUMATOID ARTHRITIS (RA)
7.1.4 INCREASING CASES OF BONE FRACTURES
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSIS AND TREATMENT OF ORTHOPEDIC DISEASES
7.2.2 RISE IN USE OF HEAVY-DUTY DRUGS IN TREATING MUSCULOSKELETAL (MSK) PAIN
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.2 USE OF TELEMEDICINE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.3 INCREASED USE OF MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.3.4 USE OF HOME HEALTHCARE FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
7.4 CHALLENGES
7.4.1 CHALLENGES FACED BY PHYSICIANS WHILE TREATING ATHLETES WITH MUSCULOSKELETAL (MSK) DISEASES
7.4.2 STRICT REGULATORY GUIDELINES FOR MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT
8 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIGITAL BIOFEEDBACK SYSTEM
8.3 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
8.3.1 IOS-SYSTEMS
8.3.2 ANDROID-SYSTEMS
8.3.3 OTHER SYSTEMS
8.4 SOLUTIONS
8.4.1 DIRECT SUPPORT
8.4.1.1 MULTIMODAL PAIN THERAPY
8.4.1.2 ONSITE PERSONALIZED THERAPY
8.4.1.3 SOLUTIONS TO REDUCE INJURIES
8.4.1.4 MIND-BODY CONNECTION IMPROVEMENT
8.4.1.5 EARLY PREVENTION AND INTERVENTION
8.4.1.6 PREVENTION, RECOVERY AND EDUCATION
8.4.1.7 PERSONALIZED PAIN RECOVERY
8.4.1.8 SENSOR-GUIDED EXERCISE THERAPY
8.4.1.9 TRAINING OF EDUCATION SKILLS
8.4.1.10 SELF-TRACKING OF PAIN EPISODES
8.4.1.11 RELAXATION TECHNIQUES
8.4.1.12 POST-OPERATIVE PAIN TRACKING
8.4.1.12.1 REAL-TIME MONITORING
8.4.1.12.2 SYMPTOM MANAGEMENT
8.4.1.13 OTHERS
8.4.2 PROGRESS TRACKING
8.4.3 OTHERS
8.5 OTHERS
9 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 PRECISION MOTION TECHNOLOGY
9.3 COMPUTER MOTION TECHNOLOGY
9.4 OTHER TECHNOLOGIES
10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE
10.1 OVERVIEW
10.2 PHONE
10.2.1 DIGITAL BIOFEEDBACK SYSTEM
10.2.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.2.3 THERAPIES
10.2.4 OTHERS
10.3 TABLET
10.3.1 DIGITAL BIOFEEDBACK SYSTEM
10.3.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.3.3 THERAPIES
10.3.4 OTHERS
10.4 COMPUTER
10.4.1 DIGITAL BIOFEEDBACK SYSTEM
10.4.2 MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS)
10.4.3 THERAPIES
10.4.4 OTHERS
10.5 OTHERS
11 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY
11.1 OVERVIEW
11.2 VIRTUAL THERAPY
11.2.1 INTERNET BASED
11.2.2 TELEPHONE BASED
11.2.3 MOBILE PHONE APPLICATION
11.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
11.2.5 INTERACTIVE VOICE RESPONSE
11.2.6 VIDEO TELECONFERENCING
11.2.7 MOBILE PHONE APPLICATION WITH TELEPHONE SUPPORT
11.2.8 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT
11.2.9 INTERNET BASED WITH VIDEO CONFERENCING
11.2.10 INTERACTIVE VOICE RESPONSE WITH TELEPHONE SUPPORT AND INTERNET BASED
11.2.11 OTHERS
11.3 IN-PERSON THERAPY
11.4 CUSTOMIZED/ PERSONALIZED THERAPY
11.5 OTHERS
12 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 PRE-SURGERY APPLICATION
12.2.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.2.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.2.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.2.5 MINIMALLY INVASIVE SPINE SURGERY
12.2.6 MOTION PRESERVING SPINE SURGERY
12.2.7 POSTERIOR CERVICAL FUSION SURGERY
12.2.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.2.9 SACROILIAC JOINT FUSION SURGERY
12.2.10 SCOLIOSIS CORRECTION SURGERY
12.2.11 VERTEBRAL AUGMENTATION SURGERY
12.2.12 FRACTURE FIXATION SURGERY
12.2.13 HIP SURGERY
12.2.13.1 TOTAL HIP REPLACEMENT
12.2.13.2 PARTIAL HIP REPLACEMENT
12.2.13.3 HIP RESURFACING
12.2.13.4 OTHERS
12.2.14 KNEE SURGERY
12.2.14.1 TOTAL KNEE REPLACEMENT
12.2.14.2 PARTIAL KNEE REPLACEMENT
12.2.14.3 MISS FUSION
12.2.14.4 OTHERS
12.3 POST-SURGERY APPLICATION
12.3.1 ANTERIOR CERVICAL DISCECTOMY AND FUSION SURGERY
12.3.2 ANTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.3 LATERAL LUMBAR INTERBODY FUSION SURGERY
12.3.4 INTERNET BASED WITH TELEPHONE SUPPORT
12.3.5 MINIMALLY INVASIVE SPINE SURGERY
12.3.6 MOTION PRESERVING SPINE SURGERY
12.3.7 POSTERIOR CERVICAL FUSION SURGERY
12.3.8 POSTERIOR LUMBAR INTERBODY FUSION SURGERY
12.3.9 SACROILIAC JOINT FUSION SURGERY
12.3.10 SCOLIOSIS CORRECTION SURGERY
12.3.11 VERTEBRAL AUGMENTATION SURGERY
12.3.12 FRACTURE FIXATION SURGERY
12.3.13 HIP SURGERY
12.3.13.1 TOTAL HIP REPLACEMENT
12.3.13.2 PARTIAL HIP REPLACEMENT
12.3.13.3 HIP RESURFACING
12.3.13.4 OTHERS
12.3.14 KNEE SURGERY
12.3.14.1 TOTAL KNEE REPLACEMENT
12.3.14.2 PARTIAL KNEE REPLACEMENT
12.3.14.3 MISS FUSION
12.3.14.4 OTHERS
13 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION
13.1 OVERVIEW
13.2 PEDIATRICS
13.2.1 MALE
13.2.2 FEMALE
13.3 ADULTS
13.3.1 MALE
13.3.2 FEMALE
13.4 GERIATRIC
13.4.1 MALE
13.4.2 FEMALE
14 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS & CLINICS
14.2.1 MULTIPLE
14.2.2 PHYSICAL THERAPIST
14.2.3 NURSE
14.2.4 HEALTH COACH
14.2.5 OTHERS
14.3 NURSING HOMES
14.3.1 MULTIPLE
14.3.2 PHYSICAL THERAPIST
14.3.3 NURSE
14.3.4 HEALTH COACH
14.3.5 OTHERS
14.4 HEALTH CENTERS
14.4.1 MULTIPLE
14.4.2 PHYSICAL THERAPIST
14.4.3 NURSE
14.4.4 HEALTH COACH
14.4.5 OTHERS
14.5 REHABILITATION CENTERS
14.5.1 MULTIPLE
14.5.2 PHYSICAL THERAPIST
14.5.3 NURSE
14.5.4 HEALTH COACH
14.5.5 OTHERS
14.6 VIRTUAL/HOME HEALTH CARE SETTINGS
14.6.1 MULTIPLE
14.6.2 PHYSICAL THERAPIST
14.6.3 NURSE
14.6.4 HEALTH COACH
14.6.5 OTHERS
14.7 OTHERS
15 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION
15.1 EUROPE
15.1.1 GERMANY
15.1.2 FRANCE
15.1.3 U.K.
15.1.4 ITALY
15.1.5 SPAIN
15.1.6 RUSSIA
15.1.7 TURKEY
15.1.8 BELGIUM
15.1.9 DENMARK
15.1.10 NETHERLANDS
15.1.11 SWITZERLAND
15.1.12 SWEDEN
15.1.13 POLAND
15.1.14 NORWAY
15.1.15 FINLAND
15.1.16 REST OF EUROPE
16 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: EUROPE
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 HINGE HEALTH, INC
18.1.1 COMPANY SNAPSHOT
18.1.2 COMPANY SHARE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.2 SWORD HEALTH, INC
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.3 OMADA HEALTHA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 COMPANY SHARE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 KAIA HEALTH
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 WELLNESS COACHES USA, LLC.
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 AIRROSTI REHAB CENTER, LLC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 DARIOHEALTH CORP.(2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 INCLUDEHEALTH (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENTS
18.9 IMC (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 PRODUCT PORTFOLIO
18.9.3 RECENT DEVELOPMENT
18.1 KIIO
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 LIMBER HEALTH, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 MOVEMENT RX (2021)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 PHZIO (2021)
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 RECOVERYONE
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 SPARTA SCIENCE
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.16 SPRITE HEALTH
18.16.1 COMPANY SNAPSHOT
18.16.2 PRODUCT PORTFOLIO
18.16.3 RECENT DEVELOPMENTS
18.17 SIMPLETHERAPY, INC.
18.17.1 COMPANY SNAPSHOT
18.17.2 PRODUCT PORTFOLIO
18.17.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
Liste des tableaux
TABLE 1 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 2 EUROPE DIGITAL BIOFEEDBACK SYSTEM IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 8 EUROPE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 11 EUROPE PRECISION MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE COMPUTER MOTION TECHNOLOGY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE OTHER TECHNOLOGIES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 15 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 17 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 23 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 25 EUROPE IN-PERSON THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 EUROPE CUSTOMIZED/ PERSONALIZED THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE HIP SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 36 EUROPE KNEE SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 38 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 40 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE GERIATRIC IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 45 EUROPE HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE HOSPITALS & CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 47 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 49 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 51 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 53 EUROPE VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 EUROPE VIRTUAL/HOME HEALTH CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 55 EUROPE OTHERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE MUSCULOSKELETAL DISEASE MANAGEMENT MARKET, BY COUNTRY, 2022-2030(USD MILLION)
TABLE 57 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 58 EUROPE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 59 EUROPE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 60 EUROPE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 61 EUROPE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 62 EUROPE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 63 EUROPE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 64 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 65 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 67 EUROPE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 70 EUROPE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 71 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 72 EUROPE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 73 EUROPE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 74 EUROPE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 75 EUROPE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 EUROPE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 EUROPE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 79 EUROPE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 80 EUROPE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 81 EUROPE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 82 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 83 EUROPE HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 84 EUROPE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 85 EUROPE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 86 EUROPE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 87 EUROPE VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 88 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 90 GERMANY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 91 GERMANY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 92 GERMANY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 93 GERMANY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 94 GERMANY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 95 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 97 GERMANY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 98 GERMANY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 101 GERMANY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 102 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 103 GERMANY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 104 GERMANY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 105 GERMANY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 106 GERMANY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 107 GERMANY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 108 GERMANY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 109 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 110 GERMANY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 111 GERMANY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 112 GERMANY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 113 GERMANY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 114 GERMANY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 115 GERMANY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 116 GERMANY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 117 GERMANY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 118 GERMANY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 119 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 120 FRANCE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 121 FRANCE DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 122 FRANCE MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 123 FRANCE SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 124 FRANCE DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 125 FRANCE POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 126 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 127 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 132 FRANCE VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 133 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 134 FRANCE PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 135 FRANCE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 136 FRANCE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 137 FRANCE POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 138 FRANCE HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 FRANCE KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 141 FRANCE PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 142 FRANCE ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 143 FRANCE GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 144 FRANCE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 145 FRANCE HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 146 FRANCE NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 147 FRANCE HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 148 FRANCE REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 149 FRANCE VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 150 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 151 U.K. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 152 U.K. DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 153 U.K. MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 154 U.K. SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 155 U.K. DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 156 U.K. POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 157 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 158 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 159 U.K. PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 160 U.K. TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 161 U.K. COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 162 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 163 U.K. VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 164 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 165 U.K. PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 166 U.K. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 167 U.K. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 168 U.K. POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 169 U.K. HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 170 U.K. KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 171 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 172 U.K. PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 173 U.K. ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 174 U.K. GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 175 U.K. MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 176 U.K. HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 177 U.K. NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 178 U.K. HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 179 U.K. REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 180 U.K. VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 181 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 182 ITALY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 183 ITALY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 184 ITALY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 185 ITALY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 186 ITALY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 187 ITALY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 189 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 190 ITALY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 194 ITALY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 195 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 196 ITALY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 197 ITALY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 198 ITALY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 199 ITALY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 200 ITALY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 201 ITALY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 202 ITALY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 203 ITALY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 204 ITALY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 205 ITALY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 206 ITALY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 207 ITALY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 208 ITALY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 209 ITALY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 210 ITALY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 211 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 212 SPAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 213 SPAIN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 214 SPAIN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 215 SPAIN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 216 SPAIN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 217 SPAIN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 219 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 220 SPAIN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 221 SPAIN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 222 SPAIN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 223 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 224 SPAIN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 225 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 226 SPAIN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 227 SPAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 228 SPAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 229 SPAIN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 230 SPAIN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 231 SPAIN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 232 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 233 SPAIN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 234 SPAIN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 235 SPAIN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 236 SPAIN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 237 SPAIN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 238 SPAIN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 239 SPAIN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 240 SPAIN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 241 SPAIN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 242 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 243 RUSSIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 244 RUSSIA DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 245 RUSSIA MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 257 RUSSIA PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 258 RUSSIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 260 RUSSIA POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 261 RUSSIA HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 263 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 264 RUSSIA PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 272 RUSSIA VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 273 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 274 TURKEY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 275 TURKEY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 276 TURKEY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 277 TURKEY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 278 TURKEY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 279 TURKEY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 280 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 281 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 282 TURKEY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 283 TURKEY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 284 TURKEY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 285 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 286 TURKEY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 287 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 TURKEY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 TURKEY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 TURKEY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 291 TURKEY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 292 TURKEY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 293 TURKEY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 294 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 295 TURKEY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 296 TURKEY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 297 TURKEY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 298 TURKEY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 299 TURKEY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 300 TURKEY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 301 TURKEY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 302 TURKEY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 303 TURKEY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 304 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 305 BELGIUM DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 306 BELGIUM DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 307 BELGIUM MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 308 BELGIUM SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 309 BELGIUM DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 310 BELGIUM POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 311 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 312 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 313 BELGIUM PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 314 BELGIUM TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 315 BELGIUM COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 316 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 317 BELGIUM VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 318 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 319 BELGIUM PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 320 BELGIUM HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 321 BELGIUM KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 322 BELGIUM POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 323 BELGIUM HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 324 BELGIUM KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 325 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 326 BELGIUM PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 327 BELGIUM ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 328 BELGIUM GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 329 BELGIUM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 330 BELGIUM HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 331 BELGIUM NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 332 BELGIUM HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 333 BELGIUM REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 334 BELGIUM VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 335 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 336 DENMARK DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 337 DENMARK DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 338 DENMARK MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 339 DENMARK SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 340 DENMARK DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 341 DENMARK POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 342 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 343 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 344 DENMARK PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 345 DENMARK TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 346 DENMARK COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 347 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 348 DENMARK VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 349 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 350 DENMARK PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 351 DENMARK HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 352 DENMARK KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 DENMARK POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 354 DENMARK HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 355 DENMARK KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 356 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 357 DENMARK PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 358 DENMARK ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 359 DENMARK GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 360 DENMARK MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 361 DENMARK HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 362 DENMARK NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 363 DENMARK HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 364 DENMARK REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 365 DENMARK VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 366 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 367 NETHERLANDS DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 368 NETHERLANDS DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 369 NETHERLANDS MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 370 NETHERLANDS SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 371 NETHERLANDS DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 372 NETHERLANDS POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 373 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 374 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 375 NETHERLANDS PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 376 NETHERLANDS TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 377 NETHERLANDS COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 378 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 379 NETHERLANDS VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 380 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 381 NETHERLANDS PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 NETHERLANDS HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 383 NETHERLANDS KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 384 NETHERLANDS POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 385 NETHERLANDS HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 386 NETHERLANDS KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 387 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 388 NETHERLANDS PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 389 NETHERLANDS ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 390 NETHERLANDS GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 391 NETHERLANDS MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 392 NETHERLANDS HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 393 NETHERLANDS NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 394 NETHERLANDS HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 395 NETHERLANDS REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 396 NETHERLANDS VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 397 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWITZERLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 399 SWITZERLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 400 SWITZERLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 401 SWITZERLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 402 SWITZERLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 403 SWITZERLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 404 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 405 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 406 SWITZERLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 407 SWITZERLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 408 SWITZERLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 409 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 410 SWITZERLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 411 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 412 SWITZERLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 413 SWITZERLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 414 SWITZERLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 415 SWITZERLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 416 SWITZERLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 417 SWITZERLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 418 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 419 SWITZERLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 420 SWITZERLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 421 SWITZERLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 422 SWITZERLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 423 SWITZERLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 424 SWITZERLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 425 SWITZERLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 426 SWITZERLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 427 SWITZERLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 428 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 429 SWEDEN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 430 SWEDEN DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 431 SWEDEN MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 432 SWEDEN SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 433 SWEDEN DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 434 SWEDEN POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 435 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 436 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 437 SWEDEN PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 438 SWEDEN TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 439 SWEDEN COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 440 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 441 SWEDEN VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 442 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 443 SWEDEN PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 444 SWEDEN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 445 SWEDEN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 446 SWEDEN POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 447 SWEDEN HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 448 SWEDEN KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 449 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 450 SWEDEN PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 451 SWEDEN ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 452 SWEDEN GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 453 SWEDEN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 454 SWEDEN HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 455 SWEDEN NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 456 SWEDEN HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 457 SWEDEN REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 458 SWEDEN VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 459 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 460 POLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 461 POLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 462 POLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 463 POLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 464 POLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 465 POLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 466 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 467 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 468 POLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 469 POLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 470 POLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 471 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 472 POLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 473 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 474 POLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 475 POLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 476 POLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 477 POLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 478 POLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 479 POLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 480 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 481 POLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 482 POLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 483 POLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 484 POLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 485 POLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 486 POLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 487 POLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 488 POLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 489 POLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 490 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 491 NORWAY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 492 NORWAY DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 493 NORWAY MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 494 NORWAY SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 495 NORWAY DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 496 NORWAY POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 497 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 498 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 499 NORWAY PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 500 NORWAY TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 501 NORWAY COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 502 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 503 NORWAY VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 504 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 505 NORWAY PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 506 NORWAY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 507 NORWAY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 508 NORWAY POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 509 NORWAY HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 510 NORWAY KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 511 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 512 NORWAY PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 513 NORWAY ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 514 NORWAY GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 515 NORWAY MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 516 NORWAY HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 517 NORWAY NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 518 NORWAY HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 519 NORWAY REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 520 NORWAY VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 521 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 522 FINLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (UNITS)
TABLE 523 FINLAND DIGITAL BIOFEEDBACK SYSTEM MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 ASP (USD)
TABLE 524 FINLAND MUSCULOSKELETAL-FOCUSED DIGITAL APPS (MDAS) IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 525 FINLAND SOLUTIONS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 526 FINLAND DIRECT SUPPORT IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY THERAPIES, 2021-2030 (USD MILLION)
TABLE 527 FINLAND POST-OPERATIVE PAIN TRACKING IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 528 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 529 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 530 FINLAND PHONE IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 531 FINLAND TABLET IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 532 FINLAND COMPUTER IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY INTEGRATION TYPE, 2021-2030 (USD MILLION)
TABLE 533 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 534 FINLAND VIRTUAL THERAPY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY MODALITY, 2021-2030 (USD MILLION)
TABLE 535 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 536 FINLAND PRE-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 537 FINLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 538 FINLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 539 FINLAND POST-SURGERY APPLICATION IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 540 FINLAND HIP SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 541 FINLAND KNEE SURGERY IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 542 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 543 FINLAND PEDIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 544 FINLAND ADULTS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 545 FINLAND GERIATRICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PATIENT POPULATION, 2021-2030 (USD MILLION)
TABLE 546 FINLAND MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 547 FINLAND HOSPITALS AND CLINICS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 548 FINLAND NURSING HOMES IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 549 FINLAND HEALTH CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 550 FINLAND REHABILITATION CENTERS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 551 FINLAND VIRTUAL HOME CARE SETTINGS IN MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY PROVIDER TYPE, 2021-2030 (USD MILLION)
TABLE 552 REST OF EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET, BY TYPE, 2021-2030 (USD MILLION)
Liste des figures
FIGURE 1 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SEGMENTATION
FIGURE 2 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: GEOGRAPHIC SCOPE
FIGURE 3 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DATA TRIANGULATION
FIGURE 4 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT
FIGURE 5 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BOTTOM-UP APPROACH
FIGURE 6 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: TOP-DOWN APPROACH
FIGURE 7 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 11 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: THE CATEGORY VS TIME GRID
FIGURE 12 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET SEGMENTATION
FIGURE 13 RISE IN AWARENESS ABOUT MUSCULOSKELETAL (MSK) DISEASES, GROWING PREVALENCE OF RHEUMATOID ARTHRITIS, TECHNOLOGICAL ADVANCEMENTS IN MUSCULOSKELETAL (MSK) DISEASES, AND STRATEGIC INITIATIVES BY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MARKET GROWTH FOR EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET IN 2023 & 2030
FIGURE 15 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET : EPIDEMIOLOGY
FIGURE 16 PREVALENCE AND INCIDENCE OF RHEUMATOID ARTHRITIS
FIGURE 17 PREVALENCE AND INCIDENCE OF OSTEOARTHRITIS
FIGURE 18 PREVALENCE AND INCIDENCE OF OSTEOPOROSIS
FIGURE 19 PREVALENCE AND INCIDENCE OF PSORIATIC ARTHRITIS
FIGURE 20 PREVALENCE AND INCIDENCE OF ANKYLOSING SPONDYLITIS
FIGURE 21 INCIDENSE OF FIBROMYALGIA
FIGURE 22 PREVALENCE AND INCIDENCE OF TENDINITIS AND CARPEL TUNNEL SYNDROME
FIGURE 23 PREVALENCE AND INCIDENCE OF BONE FRACTURES
FIGURE 24 PREVALENCE AND INCIDENCE OF OSTEOMALACIA AND OSTEOPENIA
FIGURE 25 PREVALENCE AND INCIDENCE OF GOUT
FIGURE 26 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE TRANSPLANT DIAGNOSTICS MARKET
FIGURE 27 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2022
FIGURE 28 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 29 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 30 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 31 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2022
FIGURE 32 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 33 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 34 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 35 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2022
FIGURE 36 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, 2023-2030 (USD MILLION)
FIGURE 37 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, CAGR (2023-2030)
FIGURE 38 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY INTEGRATION TYPE, LIFELINE CURVE
FIGURE 39 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2022
FIGURE 40 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, 2023-2030 (USD MILLION)
FIGURE 41 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, CAGR (2023-2030)
FIGURE 42 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY MODALITY, LIFELINE CURVE
FIGURE 43 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2022
FIGURE 44 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 45 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 46 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 47 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2022
FIGURE 48 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, 2023-2030 (USD MILLION)
FIGURE 49 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, CAGR (2023-2030)
FIGURE 50 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY PATIENT POPULATION, LIFELINE CURVE
FIGURE 51 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2022
FIGURE 52 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 53 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 54 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 55 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: SNAPSHOT (2022)
FIGURE 56 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022)
FIGURE 57 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2023 & 2030)
FIGURE 58 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY COUNTRY (2022 & 2030)
FIGURE 59 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: BY TYPE (2023-2030)
FIGURE 60 EUROPE MUSCULOSKELETAL (MSK) DISEASE MANAGEMENT MARKET: COMPANY SHARE 2022 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
